Mersana Therapeutics, Inc.
General ticker "MRSN" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $70.6M (TTM average)
Mersana Therapeutics, Inc. follows the US Stock Market performance with the rate: 22.9%.
Estimated limits based on current volatility of 1.2%: low 28.79$, high 29.50$
Factors to consider:
- Total employees count: 102 (-17.1%) as of 2024
- Top business risk factors: Regulatory and compliance, Geopolitical risks, Operational and conduct risks, Trade tariffs, Cybersecurity threats
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [17.24$, 56.86$]
- 2025-12-31 to 2026-12-31 estimated range: [11.55$, 38.71$]
Financial Metrics affecting the MRSN estimates:
- Negative: with PPE of -69.2 at the end of fiscal year the price was very high
- Negative: negative Operating income
- Negative: negative Operating cash flow
- Positive: Interest expense per share per price, % of 2.04 <= 3.30
- Positive: Industry inventory ratio change (median), % of 0 <= 0
Short-term MRSN quotes
Long-term MRSN plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $26.58MM | $36.85MM | $40.50MM |
| Operating Expenses | $230.35MM | $207.81MM | $113.83MM |
| Operating Income | $-203.77MM | $-170.96MM | $-73.34MM |
| Non-Operating Income | $-0.45MM | $-0.71MM | $4.56MM |
| Interest Expense | $3.33MM | $4.07MM | $3.87MM |
| R&D Expense | $173.38MM | $148.27MM | $73.02MM |
| Income(Loss) | $-204.21MM | $-171.67MM | $-68.77MM |
| Taxes | $0.00MM | $0.00MM | $0.42MM |
| Profit(Loss)* | $-204.21MM | $-171.67MM | $-69.19MM |
| Stockholders Equity | $92.06MM | $36.90MM | $-9.51MM |
| Assets | $334.34MM | $226.06MM | $144.66MM |
| Operating Cash Flow | $-49.36MM | $-168.88MM | $-82.34MM |
| Capital expenditure | $2.20MM | $2.17MM | $0.13MM |
| Investing Cash Flow | $-152.72MM | $119.88MM | $11.44MM |
| Financing Cash Flow | $153.02MM | $94.67MM | $4.09MM |
| Earnings Per Share** | $-54.51 | $-36.96 | $-14.12 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.